Case Report
A case report of low-dose apatinib in the treatment of advanced triple-negative breast cancer
Translational Breast Cancer Research
2024;
5:
8
(31 January 2024)
Case Report
Poland syndrome combined with breast cancer: a case report
Translational Breast Cancer Research
2024;
5:
7
(31 January 2024)
Brief Report
Can Hounsfield units on chest CT characterize breast nodules as cystic or solid?
Translational Breast Cancer Research
2024;
5:
6
(31 January 2024)
Editorial Commentary
Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer
Translational Breast Cancer Research
2024;
5:
5
(31 January 2024)
Review Article
Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives
Translational Breast Cancer Research
2024;
5:
4
(31 January 2024)
Review Article
Challenges in HER2-low breast cancer identification, detection, and treatment
Translational Breast Cancer Research
2024;
5:
3
(31 January 2024)
Review Article
Narrative review on advancing breast cancer treatment: harnessing the power of PD-1/PD-L1 inhibitors for improved patient outcomes
Translational Breast Cancer Research
2024;
5:
2
(31 January 2024)
Review Article
TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer
Translational Breast Cancer Research
2024;
5:
1
(31 January 2024)
Case Report
CDK4/6 inhibitors for primary endocrine resistant HR-positive/HER2-negative metastatic breast cancer: a case report
Translational Breast Cancer Research
2023;
4:
33
(31 October 2023)
Editorial
Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China
Translational Breast Cancer Research
2023;
4:
32
(31 October 2023)
Editorial
Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression
Translational Breast Cancer Research
2023;
4:
31
(31 October 2023)
Review Article
Androgen receptor in breast cancer and its clinical implication
Translational Breast Cancer Research
2023;
4:
30
(31 October 2023)
Review Article
A clinical perspective on oncoplastic breast conserving surgery
Translational Breast Cancer Research
2023;
4:
29
(31 October 2023)
Review Article
New-generation technologies for spatial tissue analysis, indispensable tools for deciphering intratumor heterogeneity in the development of antibody-drug conjugates and radio-immunoconjugates for cancer treatment
Translational Breast Cancer Research
2023;
4:
28
(31 October 2023)
Original Article
Self-detection remains a primary means of breast cancer detection in Beijing, China
Translational Breast Cancer Research
2023;
4:
27
(31 October 2023)
Original Article
Interaction of de novo cholesterol biosynthesis and Hippo signaling pathway in ductal carcinoma in situ (DCIS)—comparison with the corresponding normal breast epithelium
Translational Breast Cancer Research
2023;
4:
26
(31 October 2023)
Case Report
Individualize management for advanced breast cancer with pyrotinib-based anti-HER2 therapy: a case report
Translational Breast Cancer Research
2023;
4:
25
(31 July 2023)
Mini-Review
Reporting breast density on chest computed tomography
Translational Breast Cancer Research
2023;
4:
24
(31 July 2023)
Review Article
Translating new breast ultrasound techniques into clinical practice: evaluating their intended uses and describing other unexpected uses for them
Translational Breast Cancer Research
2023;
4:
23
(31 July 2023)
Review Article
Features and applications of Ehrlich tumor model in cancer studies: a literature review
Translational Breast Cancer Research
2023;
4:
22
(31 July 2023)
Review Article
Biomarkers derived from CmP signal network in triple negative breast cancers
Translational Breast Cancer Research
2023;
4:
21
(31 July 2023)
Review Article
Types and progress of clinical trial design for breast cancer: a narrative review
Translational Breast Cancer Research
2023;
4:
20
(31 July 2023)
Original Article
Real-world efficacy of postoperative radiotherapy with a moderate dose-escalation for phyllodes tumors of the breast
Translational Breast Cancer Research
2023;
4:
19
(31 July 2023)
Original Article
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial
Translational Breast Cancer Research
2023;
4:
18
(31 July 2023)
Editorial Commentary
Updates on the preoperative immunotherapy for triple-negative breast cancer
Translational Breast Cancer Research
2023;
4:
17
(30 April 2023)